RDHL Insider Trading
Insider Ownership Percentage: 6.81%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Redhill Biopharma Share Price & Price History
Current Price: $0.85
Price Change: ▲ Price Increase of +0.0466 (5.83%)
As of 04/22/2026 05:00 PM ET
Redhill Biopharma Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/6/2026 | Gilead Raday | COO | Sell | 15,740,000 | $0.00 | $0.00 | 261,060,000 |  |
Redhill Biopharma Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/13/2026 | Gagnon Securities LLC | 86,102 | $89K | 0.0% | +383.1% | 1.685% |  |
| 2/10/2026 | Yorkville Advisors Global LP | 386,593 | $0.40M | 0.3% | N/A | 7.565% | |
| 11/3/2025 | Gagnon Securities LLC | 17,822 | $39K | 0.0% | N/A | 0.535% | |
| 1/3/2025 | GAMMA Investing LLC | 5,089 | $32K | 0.0% | N/A | 0.397% | |
| 5/14/2024 | Gagnon Securities LLC | 118,360 | $63K | 0.0% | +32.1% | 0.398% | |
| 11/15/2023 | Sabby Management LLC | 635,006 | $0.32M | 0.2% | N/A | 5.736% | |
| 11/15/2023 | Armistice Capital LLC | 722,894 | $0.37M | 0.0% | N/A | 6.530% | |
| 8/7/2023 | Cowen AND Company LLC | 288,000 | $0.35M | 0.0% | N/A | 7.328% | |
| 2/7/2023 | Gagnon Securities LLC | 331,858 | $47K | 0.0% | -14.0% | 0.518% | |
| 2/7/2023 | CLARET ASSET MANAGEMENT Corp | 228,430 | $32K | 0.0% | +139.4% | 0.357% | |
| 11/7/2022 | Virtu Financial LLC | 62,182 | $31K | 0.0% | +44.8% | 0.118% | |
| 7/11/2022 | ARK Investment Management LLC | 1,045,023 | $1.17M | 0.0% | +21.3% | 1.984% | |
| 5/16/2022 | Disciplined Growth Investors Inc. MN | 1,950,002 | $4.91M | 0.1% | +0.7% | 3.701% | |
| 5/9/2022 | Gagnon Securities LLC | 367,346 | $0.93M | 0.2% | +15.4% | 0.697% | |
| 4/19/2022 | ARK Investment Management LLC | 861,798 | $2.17M | 0.0% | N/A | 1.636% | |
| 2/15/2022 | Disciplined Growth Investors Inc. MN | 1,935,589 | $4.99M | 0.1% | -2.1% | 3.694% | |
| 2/14/2022 | GSA Capital Partners LLP | 218,338 | $0.56M | 0.1% | +108.4% | 0.417% | |
| 2/10/2022 | Candriam Luxembourg S.C.A. | 71,267 | $0.18M | 0.0% | -13.6% | 0.136% | |
| 2/10/2022 | HighTower Advisors LLC | 12,300 | $32K | 0.0% | N/A | 0.023% | |
| 2/8/2022 | Gagnon Securities LLC | 318,323 | $0.82M | 0.1% | -18.8% | 0.607% | |
| 2/3/2022 | Cambridge Investment Research Advisors Inc. | 27,632 | $71K | 0.0% | N/A | 0.053% | |
Data available starting January 2016
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Read More on Redhill Biopharma
Volume
58,163 shs
Average Volume
24,760 shs
Market Capitalization
$4.33 million
P/E Ratio
0.00
Dividend Yield
N/A
Beta
4.93
Who are the company insiders with the largest holdings of Redhill Biopharma?
